CapForce (OPGN) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
1 Jun, 2026Executive summary
Completed strategic repositioning from precision medicine to financial technology and capital markets advisory, including the acquisition of iCapX and launch of digital investment banking services.
Achieved significant revenue growth in 2025, driven by listing sponsorship services and related advisory contracts, with legacy operations scaled down.
AEI Capital Ltd. became controlling shareholder, providing ongoing financial support and strategic direction.
Company now operates virtually in the U.S. and from Malaysia, focusing on Asia-Pacific capital markets.
Financial highlights
Total revenue for 2025 was $30.2 million, up from $5.2 million in 2024, primarily from listing sponsorship services.
Net income for 2025 was $23.6 million, compared to $12.0 million in 2024.
Operating expenses increased to $6.2 million in 2025 from $4.9 million in 2024, mainly due to higher service costs.
Cash and cash equivalents at year-end 2025 were $0.5 million, with access to an additional $6.5 million in equity financing from AEI Capital Ltd.
Investment in equity securities valued at $35.0 million as of December 31, 2025, received as consideration for advisory services.
Outlook and guidance
Plans to fund operations primarily through AEI Capital Ltd. until business operations are self-sustaining.
Focus on expanding digital investment banking, cross-border trading, and fintech-enabled services in Asia-Pacific.
Anticipates continued revenue growth from advisory and platform services, with a pipeline of new business opportunities.
Latest events from CapForce
- Net loss increased to $0.7 million in Q1 2026, with no revenue and continued reliance on external financing.OPGN
Q1 202612 Jun 2026 - All seven proposals, including director elections and a name change, were approved by majority vote.OPGN
AGM 202623 Feb 2026 - Shareholders will vote on seven key proposals, including a new equity plan and company name change.OPGN
Proxy Filing6 Feb 2026 - Shareholders will vote on key governance, compensation, and structural changes, including a name change.OPGN
Proxy Filing26 Jan 2026 - Q2 2025 revenue reached $4.0M from listing sponsorship, with net income of $3.5M.OPGN
Q2 202531 Oct 2025 - OpGen posted $8.9M Q3 net income, exited diagnostics, and secured $9M equity funding for fintech pivot.OPGN
Q4 202313 Jun 2025 - OpGen's revenue collapsed and liquidity remains critical as it pursues a sale or strategic transaction.OPGN
Q2 202413 Jun 2025 - Revenue plunged 82% as OpGen pivots to survival mode amid insolvencies and urgent funding needs.OPGN
Q1 202413 Jun 2025